CRL

Charles River Laboratories International, Inc.

CRL
Closed
$188.55
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,300 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Country

US

CEO

Mr. James Foster

IPO date

2000

Employees

18,300

ISIN

US1598641074

Key stats

Open

$189.28

Volume

690.55K

Market cap

$9.03B

Prev. close

$188.47

Impl / hst vl

-

Open interest

$0.00

$187.28

Day’s Range

$191.27

$146.20

52W Range

$228.88

Valuation

33
Valuation score
Overvalued
P/E
-
P/S
1.96
P/B
2.68
Current ratio
1.36
Debt / Equity
0.84
ROE
-5.74%
Gross margin
32.44%
Income growth
-94.63%
FCF growth
-125.32

Analysts estimates

Consensus rating
Buy

The average rating from top 9 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$218.22
The top 19 analysts forecasts that 12-month price may increase by 15.74%, with a low of $144.55 and a high of $278.25
$144.55
Low
$218.22
Avg
$278.25
High
Current price

Earnings

Q1 ‘26 revenue
$995.83M
Q1 ‘26 net income
-$14.84M
Revenue
Net income
Previous EPS
$2.39
Estimate EPS
$1.96
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply